No photo of Robert M. Grossberg

View Scopus Profile

Robert M. Grossberg, M.D.

  • 557 Citations
  • 9 h-Index
20042020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Robert M. Grossberg is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 3 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Publications

  • 557 Citations
  • 9 h-Index
  • 15 Article
  • 2 Letter

Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study

BEIJERINCK Investigators, May 26 2020, In : Journal of the American College of Cardiology. 75, 20, p. 2570-2584 15 p.

Research output: Contribution to journal › Article

Open Access
    • 1 Scopus citations

    Rapidly growing Mycobacterium infections after cosmetic surgery in medical tourists: the Bronx experience and a review of the literature

    Cusumano, L. R., Tran, V., Tlamsa, A., Chung, P., Grossberg, R., Weston, G. & Sarwar, U. N., Oct 2017, In : International Journal of Infectious Diseases. 63, p. 1-6 6 p.

    Research output: Contribution to journal › Article

    • 12 Scopus citations

    Oral human papillomavirus infection and oral lesions in HIV-positive and HIV-negative dental patients

    Muller, K., Kazimiroff, J., Fatahzadeh, M., Smith, R. V., Wiltz, M., Polanco, J., Grossberg, R. M., Belbin, T. J., Strickler, H. D., Burk, R. D. & Schlecht, N. F., Jan 1 2015, In : Journal of Infectious Diseases. 212, 5, p. 760-768 9 p.

    Research output: Contribution to journal › Article

    • 9 Scopus citations

    Tenofovir alafenamide: An effective option for HIV treatment with reduced risk

    Wong, D. & Grossberg, R., Sep 1 2015, In : Future Virology. 10, 9, p. 1069-1075 7 p.

    Research output: Contribution to journal › Article

    • Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study

    Castagna, A., Maggiolo, F., Penco, G., Wright, D., Mills, A., Grossberg, R., Molina, J. M., Chas, J., Durant, J., Moreno, S., Doroana, M., Ait-Khaled, M., Huang, J., Min, S., Song, I., Vavro, C., Nichols, G. & Yeo, J. M., Aug 1 2014, In : Journal of Infectious Diseases. 210, 3, p. 354-362 9 p.

    Research output: Contribution to journal › Article

    • 198 Scopus citations